Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia
    Journal Article

    Treon, S. P.; Meid, K.; Gustine, J.; Yang, G.; Xu, L.; Liu, X.; Patterson, C. J.; Hunter, Z. R.; Branagan, A. R.; Laubach, J. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib
    Journal Article

    Castillo, J. J.; Abeykoon, J. P.; Gustine, J. N.; Zanwar, S.; Mein, K.; Flynn, C. A.; Demos, M. G.; Guerrera, M. L.; Kofides, A.; Liu, X.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Journal Article

    Joffe, E.; Leyfman, Y.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Lia Palomba, M.; Moskowitz, C. H.; Portlock, C.; Noy, A.; Horwitz, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, waldenstrom's macroglobulinemia, and other non-hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A global patient-derived data registry capturing treatment, quality of life and COVID-19 data
    Meeting Abstract

    Tohidi-Esfahani, I.; Warden, A.; Malunis, E.; deNardis, P. L.; Haurat, J.; Black, M.; Opat, S.; D'Sa, S.; Kersten, M. J.; Spearing, R.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Costs of postinfusion monitoring by site of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who received third-line or later treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials
    Meeting Abstract

    Palomba, M. L.; Jun, M. P.; Garcia, J.; Lymp, J.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Nguyen, A.
    Blood (2020)

    Fulltext@MSK | Save